TopicalTherapeutic flag
Cosmetic cross-reference
Chlorhexidine
CAS 55-56-1
Chlorhexidine (CAS 55-56-1) is a Phase 4 pharmaceutical compound with 10 bioactivity targets and 3,208 adverse event associations.
SOURCE
NLM DailyMed
Label records
0
SOURCE
EMBL-EBI ChEMBL
Bioactivity
18
SOURCE
DrugCentral
Adverse signals
3,208
SOURCE
IUPHAR/BPS
PubMed IDs
1
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Chlorhexidine
CAS Number
55-56-1
UNII
R4KO0DY52L
InChIKey
GHXZTYHSJHQHIJ-UHFFFAOYSA-N
ChEMBL ID
CHEMBL790
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
chlorhexidine gluconateDyna-HexPerioChipPeriogardPeridexHibiclensExidine
natural producttherapeutic flagtopicalwithdrawn flag
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL790 | Small molecule
SOURCE
Ingredients table / CosIng profile
same-CAS cross-reference
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
SOURCE
EMBL-EBI ChEMBL
18 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 32346.399300699297 nM | 122 | - |
| - | AC50 | 13015.809010989009 nM | 91 | - |
| - | IC50 | 10749.526119402984 nM | 66 | - |
| - | MIC | 6.103767924528302 ug.mL-1 | 53 | - |
| - | EC50 | 1434.9285714285713 nM | 14 | - |
| - | Kd | 3351.467545454545 nM | 11 | - |
| - | MIC | 6650 nM | 4 | - |
| - | Ki | 2000 nM | 1 | - |
| 72 kDa type IV collagenase Enzyme |
IC50 | 5.12 | - | Homo sapiens |
| Matrix metalloproteinase-9 Enzyme |
IC50 | 5.12 | - | Homo sapiens |
| Solute carrier family 22 member 1 Transporter |
IC50 | 6.68 | - | Homo sapiens |
| Trypanothione reductase Enzyme |
Ki | 5.7 | - | Trypanosoma cruzi |
| Solute carrier family 22 member 2 Transporter |
IC50 | 6.4 | - | Homo sapiens |
| Multidrug and toxin extrusion protein 1 Transporter |
IC50 | 6.15 | - | Homo sapiens |
| Multidrug and toxin extrusion protein 2 Transporter |
IC50 | 6.3 | - | Homo sapiens |
| Solute carrier family 22 member 3 Transporter |
IC50 | 6.39 | - | Homo sapiens |
| CAAX prenyl protease 2 Enzyme |
AC50 | 5.24 | - | Saccharomyces cerevisiae (strain ATCC 204508 / S288c) |
| Synaptojanin-2 Enzyme |
IC50 | 5 | - | Homo sapiens |
SOURCE
DrugCentral
80 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Completed suicide | 4105 | 5735.419 | 10010144 |
| Drug abuse | 3174 | 4716.735 | 10013654 |
| Toxicity to various agents | 4208 | 3585.009 | 10070863 |
| Muscle injury | 1728 | 2912.499 | 10028314 |
| Folliculitis | 1801 | 2908.423 | 10016936 |
| Irritable bowel syndrome | 1809 | 2717.996 | 10023003 |
| Lower respiratory tract infection | 2140 | 2376.519 | 10024968 |
| Impaired healing | 1806 | 2250.088 | 10021519 |
| Sleep disorder due to general medical condition, insomnia type | 1332 | 2182.163 | 10040986 |
| Blister | 1859 | 1963.157 | 10005191 |
| Ill-defined disorder | 1414 | 1633.616 | 10061520 |
| Stomatitis | 1820 | 1628.479 | 10042128 |
| Gastrointestinal disorder | 1702 | 1522.332 | 10017944 |
| Duodenal ulcer perforation | 1258 | 1422.482 | 10013849 |
| Helicobacter infection | 1289 | 1408.555 | 10054263 |
| Sinusitis | 1950 | 1295.632 | 10040753 |
| Peripheral swelling | 2048 | 1065.54 | 10048959 |
| Therapeutic product effect decreased | 1664 | 1046.664 | 10082201 |
| Pericarditis | 1280 | 977.206 | 10034484 |
| Intentional overdose | 1114 | 957.284 | 10022523 |
| Anti-cyclic citrullinated peptide antibody positive | 1141 | 938.76 | 10068798 |
| Cardio-respiratory arrest | 1071 | 926.34 | 10007617 |
| Nasopharyngitis | 1871 | 892.686 | 10028810 |
| Confusional state | 2008 | 889.084 | 10010305 |
| Swelling | 1844 | 876.082 | 10042674 |
| Hypersensitivity | 1941 | 843.07 | 10020751 |
| Joint swelling | 2041 | 839.616 | 10023232 |
| Alcohol interaction | 306 | 772.092 | 10001597 |
| Pruritus | 2286 | 767.399 | 10037087 |
| Discomfort | 1289 | 752.86 | 10013082 |
| Infection | 1774 | 742.46 | 10021789 |
| Hand deformity | 1208 | 736.876 | 10061194 |
| Contusion | 1240 | 726.678 | 10050584 |
| Weight increased | 1786 | 670.229 | 10047899 |
| Synovitis | 1270 | 655.306 | 10042868 |
| Wound | 1193 | 655.052 | 10052428 |
| Glossodynia | 1221 | 654.578 | 10018388 |
| Pemphigus | 1233 | 646.191 | 10034280 |
| Hepatic enzyme increased | 1364 | 614.477 | 10060795 |
| Suspected suicide | 323 | 577.481 | 10082458 |
| Alcohol abuse | 267 | 571.862 | 10001584 |
| Systemic lupus erythematosus | 1254 | 564.756 | 10042945 |
| Suicide attempt | 763 | 539.489 | 10042464 |
| Nausea | 810 | 513.193 | 10028813 |
| Overdose | 1158 | 502.363 | 10033295 |
| Ear pain | 485 | 500.565 | 10014020 |
| Contraindicated product administered | 1287 | 490.385 | 10078504 |
| Arthropathy | 1318 | 481.828 | 10003285 |
| Muscle spasticity | 396 | 478.404 | 10028335 |
| Night sweats | 583 | 468.219 | 10029410 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
1 interaction
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TAS2R2 TAS2R2 |
Agonist | - | 28333344 |
SOURCE
NLM RxNorm
14 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CHLORHEXIDINE | 2358 | SU | MTHSPL |
| Chlorhexidine | 2358 | SU | MTHSPL |
| chlorhexidine | 2358 | SU | MTHSPL |
| chlorhexidine gluconate | 20791 | SU | MTHSPL |
| Chlorhexidine Gluconate | 20791 | SU | MTHSPL |
| CHLORHEXIDINE GLUCONATE | 20791 | SU | MTHSPL |
| chlorhexidine | 2358 | IN | RXNORM |
| chlorhexidine gluconate | 20791 | PIN | RXNORM |
| Dyna-Hex | 216813 | BN | RXNORM |
| PerioChip | 219168 | BN | RXNORM |
| Periogard | 219169 | BN | RXNORM |
| Peridex | 224891 | BN | RXNORM |
| Hibiclens | 224892 | BN | RXNORM |
| Exidine | 1661072 | BN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Abscess | chlorhexidine | LLT | C0000833 |
| Abscess | chlorhexidine | PT | C0000833 |
| Ache | chlorhexidine | LLT | C0234238 |
| Anaphylactic shock | chlorhexidine | LLT | C0002792 |
| Anaphylactic shock | chlorhexidine | PT | C0002792 |
| Anaphylactic shock | chlorhexidine | LLT | C0002792 |
| Anaphylactic shock | chlorhexidine | PT | C0002792 |
| Aphthous stomatitis | chlorhexidine | LLT | C0038363 |
| Aphthous stomatitis | chlorhexidine | PT | C0038363 |
| Arthralgia | chlorhexidine | LLT | C0003862 |
| Arthralgia | chlorhexidine | PT | C0003862 |
| Arthropathy | chlorhexidine | LLT | C0022408 |
| Arthropathy | chlorhexidine | PT | C0022408 |
| Back pain | chlorhexidine | LLT | C0004604 |
| Back pain | chlorhexidine | PT | C0004604 |
| Bronchitis | chlorhexidine | LLT | C0006277 |
| Bronchitis | chlorhexidine | PT | C0006277 |
| Burning sensation | chlorhexidine | LLT | C0085624 |
| Burning sensation | chlorhexidine | PT | C0085624 |
| Cough | chlorhexidine | LLT | C0010200 |
| Cough | chlorhexidine | PT | C0010200 |
| Deafness | chlorhexidine | LLT | C0011053 |
| Deafness | chlorhexidine | PT | C0011053 |
| Discomfort | chlorhexidine | LLT | C0234215 |
| Discomfort | chlorhexidine | PT | C0234215 |
| Dry mouth | chlorhexidine | LLT | C0043352 |
| Dry mouth | chlorhexidine | PT | C0043352 |
| Dry mouth | chlorhexidine | LLT | C0043352 |
| Dry mouth | chlorhexidine | PT | C0043352 |
| Dysgeusia | chlorhexidine | LLT | C0013378 |
| Dysgeusia | chlorhexidine | PT | C0013378 |
| Dysgeusia | chlorhexidine | LLT | C0013378 |
| Dysgeusia | chlorhexidine | PT | C0013378 |
| Dysmenorrhoea | chlorhexidine | LLT | C0013390 |
| Dysmenorrhoea | chlorhexidine | PT | C0013390 |
| Dyspepsia | chlorhexidine | LLT | C0013395 |
| Dyspepsia | chlorhexidine | PT | C0013395 |
| Erythema | chlorhexidine | LLT | C0041834 |
| Erythema | chlorhexidine | PT | C0041834 |
| Erythema | chlorhexidine | PT | C0041834 |
| Fracture | chlorhexidine | LLT | C0016658 |
| Fracture | chlorhexidine | PT | C0016658 |
| Gingival bleeding | chlorhexidine | LLT | C0017565 |
| Gingival bleeding | chlorhexidine | PT | C0017565 |
| Gingival hyperplasia | chlorhexidine | LLT | C0017566 |
| Gingival hyperplasia | chlorhexidine | PT | C0017566 |
| Glossitis | chlorhexidine | LLT | C0017675 |
| Glossitis | chlorhexidine | PT | C0017675 |
| Glossitis | chlorhexidine | LLT | C0017675 |
| Glossitis | chlorhexidine | PT | C0017675 |
| Haematuria | chlorhexidine | LLT | C0018965 |
| Haematuria | chlorhexidine | PT | C0018965 |
| Headache | chlorhexidine | LLT | C0018681 |
| Headache | chlorhexidine | PT | C0018681 |
| Hypersensitivity | chlorhexidine | LLT | C0020517 |
| Hypersensitivity | chlorhexidine | PT | C0020517 |
| Hypersensitivity | chlorhexidine | LLT | C0020517 |
| Hypersensitivity | chlorhexidine | PT | C0020517 |
| Hypertension | chlorhexidine | LLT | C0020538 |
| Hypertension | chlorhexidine | PT | C0020538 |
| Hypoaesthesia | chlorhexidine | LLT | C0020580 |
| Hypoaesthesia | chlorhexidine | PT | C0020580 |
| Hypoaesthesia | chlorhexidine | LLT | C0020580 |
| Hypoaesthesia | chlorhexidine | PT | C0020580 |
| Influenza like illness | chlorhexidine | PT | C0521839 |
| Influenza-like symptoms | chlorhexidine | LLT | C0392171 |
| Injury | chlorhexidine | PT | C3263723 |
| Injury | chlorhexidine | PT | C3263723 |
| Mouth irritation | chlorhexidine | LLT | C0235339 |
| Mouth irritation | chlorhexidine | LLT | C0235339 |
| Mouth ulceration | chlorhexidine | PT | C0149745 |
| Multiple fractures | chlorhexidine | PT | C0016655 |
| Musculoskeletal discomfort | chlorhexidine | PT | C0948594 |
| Musculoskeletal discomfort | chlorhexidine | PT | C0948594 |
| Myalgia | chlorhexidine | LLT | C0231528 |
| Myalgia | chlorhexidine | PT | C0231528 |
| Oral mucosal exfoliation | chlorhexidine | LLT | C1536052 |
| Oral mucosal exfoliation | chlorhexidine | PT | C1536052 |
| Oral mucosal exfoliation | chlorhexidine | LLT | C1536052 |
| Oral mucosal exfoliation | chlorhexidine | PT | C1536052 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Chlorhexidine used for in pharmaceutical contexts?
Chlorhexidine (CAS 55-56-1) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Chlorhexidine?
Chlorhexidine has 3,208 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Completed suicide, Drug abuse, Toxicity to various agents, Muscle injury, Folliculitis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Chlorhexidine also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Chlorhexidine with EU status "permitted".
What clinical phase is Chlorhexidine in?
Chlorhexidine is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Chlorhexidine?
Chlorhexidine has 18 bioactivity rows in this page query. Rendered target entries include 72 kDa type IV collagenase, Matrix metalloproteinase-9, Solute carrier family 22 member 1, Trypanothione reductase, Solute carrier family 22 member 2.